ArrowMark Colorado Holdings LLC Acquires 241,236 Shares of Globus Medical, Inc. $GMED

ArrowMark Colorado Holdings LLC increased its holdings in Globus Medical, Inc. (NYSE:GMED) by 25.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,202,488 shares of the medical device company’s stock after purchasing an additional 241,236 shares during the period. Globus Medical accounts for 1.3% of ArrowMark Colorado Holdings LLC’s holdings, making the stock its 19th biggest holding. ArrowMark Colorado Holdings LLC owned 0.89% of Globus Medical worth $68,866,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GMED. EverSource Wealth Advisors LLC raised its position in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. Advisors Asset Management Inc. bought a new position in shares of Globus Medical during the second quarter worth $28,000. First Horizon Corp purchased a new position in Globus Medical during the third quarter valued at $31,000. Parallel Advisors LLC grew its stake in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Globus Medical in the 3rd quarter valued at $36,000. 95.16% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

GMED has been the topic of several research analyst reports. Citigroup reiterated a “market perform” rating on shares of Globus Medical in a research note on Thursday, January 8th. Canaccord Genuity Group raised their price objective on Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Wells Fargo & Company lifted their target price on Globus Medical from $98.00 to $104.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Morgan Stanley boosted their target price on Globus Medical from $70.00 to $100.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Barclays increased their price target on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and an average price target of $104.36.

Globus Medical Price Performance

Shares of NYSE GMED opened at $84.81 on Friday. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40. The firm has a 50-day simple moving average of $90.71 and a two-hundred day simple moving average of $78.37. The company has a market cap of $11.47 billion, a P/E ratio of 21.52, a PEG ratio of 1.99 and a beta of 1.05.

Globus Medical (NYSE:GMED) last released its earnings results on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The firm had revenue of $826.42 million for the quarter, compared to analysts’ expectations of $803.29 million. During the same quarter in the prior year, the firm posted $0.84 earnings per share. The company’s quarterly revenue was up 25.7% on a year-over-year basis. As a group, equities research analysts expect that Globus Medical, Inc. will post 3.44 EPS for the current year.

Insider Activity at Globus Medical

In other Globus Medical news, Director Leslie V. Norwalk sold 2,000 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the transaction, the director owned 10,419 shares of the company’s stock, valued at $1,053,360.90. This represents a 16.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Kelly Huller sold 20,000 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 35,594 shares of company stock worth $3,332,253 in the last quarter. 18.51% of the stock is owned by company insiders.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a “Strong‑Buy” rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average “Moderate Buy” rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.